FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W103484934> ?p ?o ?g. }

• W103484934 endingPage "520" @default.
• W103484934 startingPage "514" @default.
• W103484934 abstract "Objective To determine the efficacy, tolerance and safety of intramuscular injections of porcine type I collagen-PVP in patients with RA in a long term-therapy. Methods The study was a double blind placebo-controlled and included 30 patients with active RA (ACR). Patients were treated with intramuscular injections of 2 ml of collagen-PVP (3.4 mg of collagen) or 2 ml of placebo during 6 months. The follow up was done during the next 6 months. The primary endpoints included the Ritchie index (RI), swollen joint count, disease activity score (DAS), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). The secondary endpoints included morning stiffness, pain intensity on a visual analogue scale (VAS), and Spanish-health assessment questionnaire (HAQ-DI). Improvement was determined using American College of Rheumatology response criteria (ACR20, 50 and 70). Results Collagen-PVP was safe and well tolerated. There were no adverse events. Patients had a statistically significant improvement (p < 0.05) in collagen-PVP-treated vs. placebo at 6 months of treatment in: swollen joint count (7.1 ± 0.8 vs. 16.0 ± 1.6), RI (8.1 ± 0.8 vs. 15.2 ± 1.5), morning stiffness (9.2 ± 3.1 vs. 29.1 ± 5.9 min), HAQ-DI (50.0 ± 10.8 vs. 22.9 ± 10.3), DAS (3.0 ± 0.2 vs. 4.9 ± 0.3), ACR20 (78.6 vs. 71.4%), ACR50 (57.1 vs. 0%) and ACR70 (7.1 vs. 0%) and CRP (1.1 ± 0.4 vs. 2.5 ± 0.7). Patients treated with collagen-PVP required lower doses of methotrexate vs. placebo (12.6 ± 0.6 vs. 14.2 ± 0.7 at 6 months and 12.3 ± 0.8 vs. 15.4 ± 0.6 at 12 months; p < 0.05). Serological or haematological parameters remained unchanged. Conclusion Collagen-PVP has been shown to be a safe and well-tolerated drug for the long-term treatment of RA. Combination of collagen-PVP plus methotrexate was more efficacious than methotrexate alone. This biodrug can be useful in the treatment of RA." @default.
• W103484934 created "2016-06-24" @default.
• W103484934 creator A5020396507 @default.
• W103484934 creator A5040618431 @default.
• W103484934 creator A5041707507 @default.
• W103484934 creator A5065112792 @default.
• W103484934 creator A5073497119 @default.
• W103484934 creator A5082235231 @default.
• W103484934 creator A5083140774 @default.
• W103484934 date "2006-09-01" @default.
• W103484934 modified "2023-10-03" @default.
• W103484934 title "Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial." @default.
• W103484934 cites W101111287 @default.
• W103484934 cites W149687974 @default.
• W103484934 cites W184648558 @default.
• W103484934 cites W1935724085 @default.
• W103484934 cites W1967201035 @default.
• W103484934 cites W1983510723 @default.
• W103484934 cites W1988985090 @default.
• W103484934 cites W2000433942 @default.
• W103484934 cites W2045502143 @default.
• W103484934 cites W2050390987 @default.
• W103484934 cites W2066668926 @default.
• W103484934 cites W2068469424 @default.
• W103484934 cites W2072200803 @default.
• W103484934 cites W2073879836 @default.
• W103484934 cites W2114212184 @default.
• W103484934 cites W2116843833 @default.
• W103484934 cites W2151314998 @default.
• W103484934 cites W2152348310 @default.
• W103484934 cites W2228376033 @default.
• W103484934 cites W2325910314 @default.
• W103484934 cites W2396288232 @default.
• W103484934 cites W2410707014 @default.
• W103484934 cites W2438903808 @default.
• W103484934 cites W590219172 @default.
• W103484934 cites W64264580 @default.
• W103484934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17181919" @default.
• W103484934 hasPublicationYear "2006" @default.
• W103484934 type Work @default.
• W103484934 sameAs 103484934 @default.
• W103484934 citedByCount "3" @default.
• W103484934 countsByYear W1034849342020 @default.
• W103484934 countsByYear W1034849342022 @default.
• W103484934 crossrefType "journal-article" @default.
• W103484934 hasAuthorship W103484934A5020396507 @default.
• W103484934 hasAuthorship W103484934A5040618431 @default.
• W103484934 hasAuthorship W103484934A5041707507 @default.
• W103484934 hasAuthorship W103484934A5065112792 @default.
• W103484934 hasAuthorship W103484934A5073497119 @default.
• W103484934 hasAuthorship W103484934A5082235231 @default.
• W103484934 hasAuthorship W103484934A5083140774 @default.
• W103484934 hasConcept C126322002 @default.
• W103484934 hasConcept C141071460 @default.
• W103484934 hasConcept C14184104 @default.
• W103484934 hasConcept C142724271 @default.
• W103484934 hasConcept C168563851 @default.
• W103484934 hasConcept C197934379 @default.
• W103484934 hasConcept C198451711 @default.
• W103484934 hasConcept C202061045 @default.
• W103484934 hasConcept C203092338 @default.
• W103484934 hasConcept C204787440 @default.
• W103484934 hasConcept C27081682 @default.
• W103484934 hasConcept C2777575956 @default.
• W103484934 hasConcept C2778143017 @default.
• W103484934 hasConcept C2991744798 @default.
• W103484934 hasConcept C71924100 @default.
• W103484934 hasConcept C90924648 @default.
• W103484934 hasConceptScore W103484934C126322002 @default.
• W103484934 hasConceptScore W103484934C141071460 @default.
• W103484934 hasConceptScore W103484934C14184104 @default.
• W103484934 hasConceptScore W103484934C142724271 @default.
• W103484934 hasConceptScore W103484934C168563851 @default.
• W103484934 hasConceptScore W103484934C197934379 @default.
• W103484934 hasConceptScore W103484934C198451711 @default.
• W103484934 hasConceptScore W103484934C202061045 @default.
• W103484934 hasConceptScore W103484934C203092338 @default.
• W103484934 hasConceptScore W103484934C204787440 @default.
• W103484934 hasConceptScore W103484934C27081682 @default.
• W103484934 hasConceptScore W103484934C2777575956 @default.
• W103484934 hasConceptScore W103484934C2778143017 @default.
• W103484934 hasConceptScore W103484934C2991744798 @default.
• W103484934 hasConceptScore W103484934C71924100 @default.
• W103484934 hasConceptScore W103484934C90924648 @default.
• W103484934 hasIssue "5" @default.
• W103484934 hasLocation W1034849341 @default.
• W103484934 hasLocation W1034849342 @default.
• W103484934 hasOpenAccess W103484934 @default.
• W103484934 hasPrimaryLocation W1034849341 @default.
• W103484934 hasRelatedWork W1967201035 @default.
• W103484934 hasRelatedWork W1975524677 @default.
• W103484934 hasRelatedWork W1988985090 @default.
• W103484934 hasRelatedWork W1997317029 @default.
• W103484934 hasRelatedWork W2000433942 @default.
• W103484934 hasRelatedWork W2010621423 @default.
• W103484934 hasRelatedWork W2042771149 @default.
• W103484934 hasRelatedWork W2071643977 @default.
• W103484934 hasRelatedWork W2072200803 @default.

• next